Portage Biotech, Inc. (PRTG)

NASDAQ: PRTG · IEX Real-Time Price · USD
6.24
+0.35 (5.94%)
Sep 28, 2022 3:59 PM EDT - Market closed
5.94%
Market Cap 105.73M
Revenue (ttm) n/a
Net Income (ttm) -17.83M
Shares Out 16.94M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,227
Open 5.85
Previous Close 5.89
Day's Range 5.85 - 6.46
52-Week Range 4.62 - 23.99
Beta 122.40
Analysts Buy
Price Target 25.16 (+303.2%)
Earnings Date Aug 29, 2022

About PRTG

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT23... [Read more...]

Industry Biotechnology
Founded 1973
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PRTG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for PRTG stock is "Buy." The 12-month stock price forecast is 25.16, which is an increase of 303.21% from the latest price.

Price Target
$25.16
(303.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 268%

The consensus price target hints at a 268.4% upside potential for Portage Biotech Inc. (PRTG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

1 week ago - Zacks Investment Research

Bears are Losing Control Over Portage Biotech Inc. (PRTG), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Portage Biotech Inc. (PRTG), indicating that the stock has found support. This, combined with an upward trend in earnings estim...

1 week ago - Zacks Investment Research

Portage Biotech Provides Research and Development Update

--The Company Highlights its Clinical Strategy for its Adenosine and iNKT Platforms-- --Clinical Development Goals are Focused on Producing Phase 1b/Phase 2 Efficacy Readouts in Multiple Tumor Types Ove...

2 weeks ago - GlobeNewsWire

Portage Biotech to Present at Upcoming Investor Conferences

WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, tod...

2 weeks ago - GlobeNewsWire

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and...

4 weeks ago - GlobeNewsWire

Portage Biotech Announces Leadership Updates

CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board

1 month ago - GlobeNewsWire

Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?

The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

1 month ago - Zacks Investment Research

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets--

1 month ago - GlobeNewsWire

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets--

1 month ago - GlobeNewsWire

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT ago...

2 months ago - Benzinga

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stock Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of eq...

2 months ago - GlobeNewsWire

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration

2 months ago - GlobeNewsWire

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

Preliminary data from the Phase 1/2 trial of PORT-2 demonstrates favorable safety and tolerability as a monotherapy with translational data supporting its mechanism of action Preliminary data from the P...

3 months ago - GlobeNewsWire

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines

5 months ago - GlobeNewsWire

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual...

Late-breaking preclinical data generated by Stimunity suggests that packaging cGAMP STING activator in a virus-like particle leads to activation of tumor-specific T cells Late-breaking preclinical data ...

5 months ago - GlobeNewsWire

Portage Biotech Provides Update on Clinical-Stage and Development Programs

Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development

5 months ago - GlobeNewsWire

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

Preclinical data will be presented in a late-breaking abstract session Preclinical data will be presented in a late-breaking abstract session

6 months ago - GlobeNewsWire

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022 Company working to accelerate lead clinical programs; expects multiple clinical readouts in 2022

7 months ago - GlobeNewsWire

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

Leading biopharma executive Brian Wiley joins as Chief Business Officer

7 months ago - GlobeNewsWire

Portage Biotech Announces Participation in January 2022 Investor Conferences

WESTPORT, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient live...

8 months ago - GlobeNewsWire

Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year

WESTPORT, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient live...

10 months ago - GlobeNewsWire

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient live...

10 months ago - GlobeNewsWire

Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT-1...

WESTPORT, Conn., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient liv...

10 months ago - GlobeNewsWire

Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment

Thursday, November 18th @ 10amET Thursday, November 18th @ 10amET

10 months ago - GlobeNewsWire

Portage Biotech Announces Participation in September 2021 Investor Conferences

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and...

1 year ago - GlobeNewsWire